SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under ...

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report ...

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...